Other antiviral compounds
K |
|||
| (7 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt) | |||
| Zeile 1: | Zeile 1: | ||
| − | {{ | + | {{up|PHA antivirals by mechanism}} |
| + | |||
| + | |||
| + | |||
{{tp|p=32248766|t=2020. Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19 |pdf=|usr=}} | {{tp|p=32248766|t=2020. Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19 |pdf=|usr=}} | ||
{{tp|p=32429580|t=2020. Comparative Antiviral Activity of Remdesivir and Anti-HIV Nucleoside Analogs Against Human Coronavirus 229E (HCoV-229E).|pdf=|usr=007}} | {{tp|p=32429580|t=2020. Comparative Antiviral Activity of Remdesivir and Anti-HIV Nucleoside Analogs Against Human Coronavirus 229E (HCoV-229E).|pdf=|usr=007}} | ||
| Zeile 16: | Zeile 19: | ||
{{tp|p=32495926|t=2020. Does amantadine have a protective effect against COVID-19?|pdf=|usr=007}} | {{tp|p=32495926|t=2020. Does amantadine have a protective effect against COVID-19?|pdf=|usr=007}} | ||
{{tp|p=32436995|t=2020. The potential of memantine and related adamantanes such as amantadine, to reduce the neurotoxic effects of COVID-19, including ARDS and to reduce viral replication through lysosomal effects.|pdf=|usr=007}} | {{tp|p=32436995|t=2020. The potential of memantine and related adamantanes such as amantadine, to reduce the neurotoxic effects of COVID-19, including ARDS and to reduce viral replication through lysosomal effects.|pdf=|usr=007}} | ||
| + | {{tp|p=32571606|t=2020. Amantadine Treatment for People with COVID-19.|pdf=|usr=011}} | ||
| + | {{tp|p=32542661|t=2020. Use of amantadine in a patient with SARS-CoV-2.|pdf=|usr=011}} | ||
| + | |||
'''Auranofin''' | '''Auranofin''' | ||
{{tp|p=32442105|t=2020. The FDA-approved gold drug auranofin inhibits novel coronavirus (SARS-COV-2) replication and attenuates inflammation in human cells.|pdf=|usr=007}} | {{tp|p=32442105|t=2020. The FDA-approved gold drug auranofin inhibits novel coronavirus (SARS-COV-2) replication and attenuates inflammation in human cells.|pdf=|usr=007}} | ||
| + | |||
| + | '''Baloxavir''' | ||
| + | {{tp|p=32487990|t=2020. Modeling mitigation of influenza epidemics by baloxavir.|pdf=|usr=007}} | ||
| + | |||
| + | |||
| + | |||
| + | '''Didanosine''' | ||
| + | {{tp|p=32291351|t=2020. Repurposing Didanosine as a Potential Treatment for COVID-19 Using Single-Cell RNA Sequencing Data |pdf=|usr=}} | ||
| + | |||
| + | |||
| + | |||
| Zeile 26: | Zeile 43: | ||
{{tp|p=32361588|t=2020. Plausible mechanisms of Niclosamide as an antiviral agent against COVID-19 |pdf=|usr=}} | {{tp|p=32361588|t=2020. Plausible mechanisms of Niclosamide as an antiviral agent against COVID-19 |pdf=|usr=}} | ||
| − | |||
| − | |||
| − | |||
| + | '''Novirin''' | ||
| + | {{tp|p=32283177|t=ä. Coronavirus (COVID-19), First Indication of Efficacy of Gene-Eden-VIR/Novirin in SARS-CoV-2 Infections |pdf=|usr=}} | ||
| − | |||
| − | |||
| − | ''' | + | '''Silibinin''' |
| − | {{tp|p= | + | {{tp|p=32517353|t=2020. Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm and Virus Replication Machinery for Clinical Management of COVID-19 Patients.|pdf=|usr=008}} |
| − | |||
| − | |||
| − | ''' | + | |
| − | {{tp|p= | + | |
| + | '''Suramin''' | ||
| + | {{tp|p=32513797|t=2020. Suramin inhibits SARS-CoV-2 infection in cell culture by interfering with early steps of the replication cycle.|pdf=|usr=008}} | ||
| + | |||
'''Tilorone''' | '''Tilorone''' | ||
| Zeile 51: | Zeile 66: | ||
| − | ''' | + | |
| − | {{tp|p= | + | |
| + | |||
| + | |||
| + | |||
| + | |||
| + | '''Anti HCV nucleotides''' | ||
| + | {{tp|p=32119961|t=2020. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19 |pdf=|usr=}} | ||
| + | |||
| + | |||
'''NHC''' | '''NHC''' | ||
{{tp|p=32253226|t=ä. (β-D-N4-hydroxycytidine (NHC, EIDD-1931) An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice |pdf=|usr=}} | {{tp|p=32253226|t=ä. (β-D-N4-hydroxycytidine (NHC, EIDD-1931) An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice |pdf=|usr=}} | ||
{{tp|p=32253226|t=ä. (NHC, EIDD-1931) An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice |pdf=|usr=}} | {{tp|p=32253226|t=ä. (NHC, EIDD-1931) An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice |pdf=|usr=}} | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| Zeile 70: | Zeile 86: | ||
'''beta ketoamides''' | '''beta ketoamides''' | ||
{{tp|p=32045235|t=ä. ?-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment |pdf=|usr=}} | {{tp|p=32045235|t=ä. ?-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment |pdf=|usr=}} | ||
| − | |||
| − | |||
| − | |||
'''some lipids''' | '''some lipids''' | ||
| Zeile 81: | Zeile 94: | ||
'''-''' | '''-''' | ||
| + | {{tp|p=32452420|t=2020. Antiviral activity of lycorine against Zika virus in vivo and in vitro |pdf=|usr=}} | ||
{{tp|p=31073993|t=2019. (x)Synthesis and anti?coronavirus activity of a series of 1?thia?4?azaspiro 4 5 decan?3?one derivatives |pdf=|usr=}} | {{tp|p=31073993|t=2019. (x)Synthesis and anti?coronavirus activity of a series of 1?thia?4?azaspiro 4 5 decan?3?one derivatives |pdf=|usr=}} | ||
{{tp|p=28945945|t=2017. Macromolecular Antiviral Agents against Zika, Ebola, SARS, and Other Pathogenic Viruses |pdf=|usr=}} | {{tp|p=28945945|t=2017. Macromolecular Antiviral Agents against Zika, Ebola, SARS, and Other Pathogenic Viruses |pdf=|usr=}} | ||
Aktuelle Version vom 11. April 2021, 16:33 Uhr
| PHA antivirals by mechanism |
32248766 2020. Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19
32429580 2020. Comparative Antiviral Activity of Remdesivir and Anti-HIV Nucleoside Analogs Against Human Coronavirus 229E (HCoV-229E).
32423027 2020. COVID-19: An Update About the Discovery Clinical Trial.
32023685 2020. [Potential antiviral therapeutics for 2019 Novel Coronavirus].
32432977 2020. Gemcitabine, lycorine and oxysophoridine inhibit novel coronavirus (SARS-CoV-2) in cell culture.
32501538 2020. A comparative study on the time to achieve negative nucleic acid testing and hospital stays between Danoprevir and Lopinavir/Ritonavir in the treatment of patients with COVID-19.
32495848 2020. Editorial - Sofosbuvir/Velpatasvir as a combination with strong potential activity against SARS-CoV2 (COVID-19) infection: how to use direct-acting antivirals as broad-spectrum antiviral agents.
Amantadine
32361028 ä. Amantadine disrupts lysosomal gene expression; a hypothesis for COVID19 treatment ?
32361100 2020. Amantadine as a drug to mitigate the effects of COVID-19
32176361 2020. Potentially repurposing adamantanes for COVID-19
32495926 2020. Does amantadine have a protective effect against COVID-19?
32436995 2020. The potential of memantine and related adamantanes such as amantadine, to reduce the neurotoxic effects of COVID-19, including ARDS and to reduce viral replication through lysosomal effects.
32571606 2020. Amantadine Treatment for People with COVID-19.
32542661 2020. Use of amantadine in a patient with SARS-CoV-2.
Auranofin
32442105 2020. The FDA-approved gold drug auranofin inhibits novel coronavirus (SARS-COV-2) replication and attenuates inflammation in human cells.
Baloxavir
32487990 2020. Modeling mitigation of influenza epidemics by baloxavir.
Didanosine
32291351 2020. Repurposing Didanosine as a Potential Treatment for COVID-19 Using Single-Cell RNA Sequencing Data
Niclosamide
32125140 ä. Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential
32361588 2020. Plausible mechanisms of Niclosamide as an antiviral agent against COVID-19
Novirin
32283177 ä. Coronavirus (COVID-19), First Indication of Efficacy of Gene-Eden-VIR/Novirin in SARS-CoV-2 Infections
Silibinin
32517353 2020. Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm and Virus Replication Machinery for Clinical Management of COVID-19 Patients.
Suramin
32513797 2020. Suramin inhibits SARS-CoV-2 infection in cell culture by interfering with early steps of the replication cycle.
Tilorone
32215760 2020. Tilorone: a Broad-Spectrum Antiviral Invented in the USA and Commercialized in Russia and beyond
32205350 2020. Tilorone, a Broad-Spectrum Antiviral for Emerging Viruses
Anti HCV nucleotides
32119961 2020. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19
NHC
32253226 ä. (β-D-N4-hydroxycytidine (NHC, EIDD-1931) An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice
32253226 ä. (NHC, EIDD-1931) An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice
beta ketoamides
32045235 ä. ?-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment
some lipids
32229155 2020. Can Bioactive Lipids Inactivate Coronavirus (COVID-19)?
phenantroids
20727913 2010. (x)Identification of phenanthroindolizines and phenanthroquinolizidines as novel potent anti-coronaviral agents for porcine enteropathogenic coronavirus transmissible gastroenteritis virus and human severe acute respiratory syndrome coronavirus
-
32452420 2020. Antiviral activity of lycorine against Zika virus in vivo and in vitro
31073993 2019. (x)Synthesis and anti?coronavirus activity of a series of 1?thia?4?azaspiro 4 5 decan?3?one derivatives
28945945 2017. Macromolecular Antiviral Agents against Zika, Ebola, SARS, and Other Pathogenic Viruses
